MaxCyte, Inc. (MXCT) stock

MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 11/3065% below fair value

$1.10−0.03 (-2.65%)

Close on Nov 11, 2026Market cap $113.53MP/E –Yield –

MaxCyte r&d expenses

Research and development expenses are spending on new products and technology.

MaxCyte's R&D Expenses for the twelve months ending Sep 30, 2026 was $14.32M, down 35.2% year over year. For fiscal 2025 it was $20.82M, down 6.3% from the year before. The highest annual figure on record is $23.82M in fiscal 2023.

Annual r&d expenses

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$20.82M	-6.3%
FY2024	Dec 31, 2024	$22.23M	-6.7%
FY2023	Dec 31, 2023	$23.82M	+22.1%
FY2022	Dec 31, 2022	$19.51M	+26.7%
FY2021	Dec 31, 2021	$15.41M	-13.1%
FY2020	Dec 31, 2020	$17.73M	+0.8%
FY2019	Dec 31, 2019	$17.59M	–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	$2.87M	-45.9%
Q2 FY2026	Jun 30, 2026	$4.25M	-32.2%
Q1 FY2026	Mar 31, 2026	$3.86M	-34.7%
Q4 FY2025	Dec 31, 2025	$3.34M	-27.7%
Q3 FY2025	Sep 30, 2025	$5.32M	0.0%
Q2 FY2025	Jun 30, 2025	$6.27M	+11.6%
Q1 FY2025	Mar 31, 2025	$5.90M	-11.6%
Q4 FY2024	Dec 31, 2024	$4.61M	-21.0%
Q3 FY2024	Sep 30, 2024	$5.32M	-15.1%
Q2 FY2024	Jun 30, 2024	$5.62M	-0.8%
Q1 FY2024	Mar 31, 2024	$6.68M	+10.4%
Q4 FY2023	Dec 31, 2023	$5.84M	+2.0%
Q3 FY2023	Sep 30, 2023	$6.26M	+17.6%
Q2 FY2023	Jun 30, 2023	$5.66M	+20.6%
Q1 FY2023	Mar 31, 2023	$6.05M	+60.6%
Q4 FY2022	Dec 31, 2022	$5.73M	+69.5%
Q3 FY2022	Sep 30, 2022	$5.33M	+93.9%
Q2 FY2022	Jun 30, 2022	$4.70M	+46.6%
Q1 FY2022	Mar 31, 2022	$3.77M	-38.0%
Q4 FY2021	Dec 31, 2021	$3.38M	-30.8%
Q3 FY2021	Sep 30, 2021	$2.75M	-39.2%
Q2 FY2021	Jun 30, 2021	$3.20M	-21.7%
Q1 FY2021	Mar 31, 2021	$6.08M	–
Q4 FY2020	Dec 31, 2020	$4.88M	–
Q3 FY2020	Sep 30, 2020	$4.52M	–
Q2 FY2020	Jun 30, 2020	$4.09M	–